Shell shock: army’s $500m plant flops, czech rival rises
The gist
While the Army’s $500 million Texas plant floundered with zero compliant shells and malfunctioning robots, a Czech-built Iowa facility is poised to revolutionize U.S. artillery production with modern methods and real results.
What to know
- General Dynamics’ much-hyped Mesquite plant failed to deliver a single usable shell in seven months, despite a $533 million price tag and urgent demand.
- The Army’s gamble on retrofitted World War II-era equipment and unproven automation led to output bottlenecks, with production stuck at just one-third of the 100,000-shell monthly target by March 2026.
- Meanwhile, the Czech CSG facility in Iowa aims for 36,000 shells per month using selective automation—putting the U.S. back on track to outpace global rivals by 2029.
Old Tech, New Headaches
The Army’s decision to retrofit WWII-era shell equipment backfired, creating crippling production bottlenecks and forcing outdated plants to pick up the slack.
The U.S. Army's ambitious goal of producing 100,000 155mm shells monthly was critically undermined by the decision to rely on adapting obsolete World War II-era M107 shell manufacturing equipment. Contractors purchased and attempted to retrofit this outdated machinery, a strategy approved by the Army procurement department to expedite production. However, this gamble backfired spectacularly, as no compliant parts were produced over a seven-month period, exemplified by the Mesquite plant's failure to deliver a single technically compliant projectile part despite its planned monthly output of 30,000 shells.
The root of these production bottlenecks lies in the M107 shell's nearly 70-year-old design, which features a heavy and technologically outdated manufacturing process ill-suited for modern adaptation. While some components could be retrofitted, many required more time and effort to produce than acquiring new, specialized equipment would have demanded. This mismatch created inefficiencies that cascaded across multiple facilities, including Scranton and Wilkes-Barre, which struggled to compensate for Mesquite's shortfalls, collectively limiting output to just 36,000 rounds per month by March 2026—roughly one-third of the target.
Despite a substantial $469 million investment in the state-of-the-art, highly automated Mesquite plant, which opened in 2024 with the expectation of accelerating M107 shell body production, the facility failed to meet its production schedule. This failure forced older plants, including those in Scranton, Wilkes-Barre, and even Ingersoll, Canada, to shoulder additional workload, yet these efforts were insufficient to close the production gap. The reliance on legacy equipment and failure to modernize shell body manufacturing processes thus emerged as a critical bottleneck in the U.S. artillery ammunition ramp-up.
Automation Meltdown in Texas
Unproven robotics and lax oversight at the $533M Mesquite plant led to dangerous breakdowns and zero usable shells, yet contractors faced no real consequences.
The $533 million General Dynamics artillery shell plant in Mesquite, Texas, intended to supply shells for Ukraine, stands as a stark example of modern automation failure, having produced no usable shells by August 2025. This ambitious facility was plagued by unproven automation technology that frequently malfunctioned, with robot arms swinging out of control and even catching fire, forcing costly production stoppages and raising serious safety concerns. The reliance on manual fixes, such as pounding giant press machines with sledgehammers, underscored a glaring absence of standardized manufacturing processes in what was supposed to be a cutting-edge operation.
Despite the catastrophic failure of the Mesquite plant, General Dynamics faced no financial repercussions and continued to secure Pentagon contracts, revealing systemic shortcomings in defense contracting accountability. The Army’s oversight was notably inadequate; inspector general reports were vague and lacked actionable recommendations, while Army officials deflected blame rather than implementing decisive corrective measures. This pattern of unaddressed failure and lack of transparency highlights deep-rooted issues within the Pentagon’s management of modernization efforts and contractor performance.
Czech Plant Rewrites the Playbook
Iowa’s CSG facility blends selective automation with modern safety standards, setting a new benchmark for U.S. artillery production and breaking decades-old bottlenecks.
The Czech CSG Future Artillery Complex in Iowa stands as a cornerstone in the U.S. Army’s ambitious plan to modernize and vastly expand 155 mm artillery shell production, aiming to reach a staggering 432,000 rounds annually by 2029. This facility alone is designed to load explosives into up to 36,000 shells per month, directly supporting the Army’s broader objective of producing 100,000 rounds monthly and addressing long-standing bottlenecks in load and fill operations, as emphasized by Maj. Brian K. Schwartzkopf.
Marking a significant departure from decades-old manual production methods dating back to the 1940s, the CSG Iowa plant will selectively integrate automation to enhance safety, efficiency, and product consistency. This nuanced approach to modernization reflects a strategic balance—leveraging technology 'where it makes sense'—to maintain reliability while boosting throughput in a facility expected to operate for at least 50 years.
The U.S. commitment to artillery ammunition modernization extends beyond the CSG Iowa complex, with substantial investments such as the $469 million General Dynamics Mesquite plant and efforts to onshore propellant production. These initiatives collectively aim to catapult monthly 155 mm shell output from a mere 14,000 rounds to 100,000 by October 2025, underscoring a determined push to overcome production challenges and reduce reliance on foreign suppliers.
In scale and ambition, the CSG Iowa facility dwarfs comparable allied efforts, exemplifying the U.S.’s unmatched dedication to artillery ammunition production. While the UK’s Glascoed plant targets approximately 80,000 shells annually even at its upper capacity, the Iowa complex alone is contracted to load over five times that amount, signaling a strategic prioritization of large-scale, resilient domestic manufacturing capacity.